NCT02153450View on ClinicalTrials.gov

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

August 3, 2018

Study Completion Date

June 13, 2020

Conditions
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage I-III Pancreatic Cancer
Interventions
DRUG

metformin hydrochloride

Given PO

RADIATION

stereotactic radiosurgery

Undergo stereotactic radiosurgery

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT02153450 - Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter